Laekna (HKG:2105) has enrolled its first subject in a Phase I clinical trial evaluating LAE118, the company's proposed treatment for solid tumors, in China, according to a Hong Kong bourse filing on Tuesday.
LAE118 currently has investigational new drug approval from health regulators in China and the U.S.